PURPOSE:
Induction of long term transplant survival by "costimulation blockade" (CoB) regimens is impaired by inflammatory responses. In particular, multiple studies reported that engagement of toll like receptors (TLR) abrogate the tolerogenic effect of CoB. Despite the identification of type-1 interferons (TI-IFN) as mediators of this effect in multiple models, their target population and specific pathway used remain undefined. To better understand how TI-IFN could interfere with the induction of transplant tolerance, we studied their impact on the immunomodulatory properties of IL-10.
METHODS:
Full mismatch skin transplants were performed using dorsal skin from Balb/c into C57BL/6 mice and animals received a peri-transplant regimen based on DST (10 7 T-depleted splenocytes; on day 0) and anti-CD154 mAb (MR-1; on day 0, 7, 14) +/-anti-IL-10R (on day 0, 7, 14). Mouse T cells were isolated by negative-selection and Tmem and Treg subsets identified by flow cytometry. IL-10R expression and phospho-STAT3 induction after IL-10 or IL-6 stimulation in T cells were measured via flow cytometry. The gene expression profile of T cell subsets exposed to TI-IFN was assessed by microarray and quantitative PCR analysis. Protein levels were measured by Western Blot.
RESULTS:
Our result showed that IL-10 has a fundamental role in the protective effect of CoB (transplant survival:
MST 105d with CoB vs 47d with anti-IL-10R administration). We then studied the impact of T cell exposure to TI-IFN on IL-10 signaling. Following 48h of in vitro incubation with IFN-β, memory T cells (Tmem) and Tregs presented a dramatic defect in the production of phospho-STAT3 in response to IL-10. This effect was very selective, as IL-6 signaling (post IFN-β exposure) induced normal levels of phospho-STAT3. The reduced accumulation of phospho-STAT3 in conditioned cells resulted in the inhibition of the upregulation of mRNAs for LIGHT, Sphk1 and Tarm-1 -three genes we have discovered are induced by IL-10 in T cells. Encouragingly, this effect was slowly reversible with removal of TI-IFN, suggesting a "druggable" pathway. Microarray and flow cytometry data indicated that this IL-10-specific unresponsiveness was not associated with any reduction of IL-10 receptor expression or an increase in SOCS (Suppressor of Cytokine Signaling) 1 and 3, nor with reduced STAT3 cytoplasmic availability. Instead, this analysis suggested a novel role for the transcription factor STAT1 in dampening IL-10 signaling. Using T cells from STAT1-KO mice, we show that the absence of STAT1 prevented IL-10 inhibition induced by IFN-β in Treg and Tmem, supporting our new model.
CONCLUSION:
Overall, these results highlight the importance of IL-10 in the therapeutic effect of CoB regimens and reveal a new molecular mechanism whereby TI-IFN interfere with IL-10 signaling, and ultimately with regulation of alloreactivity. Identifying a strategy to target this mechanism could provide a valuable aid in the clinical efficacy of CoB-based immunomodulatory strategies.
Targeting Wnt Signaling to Reduce Capsular Fibrosis
Britta A. Kuehlmann, MD, PhD, Clark Andrew Bonham, Geoffrey C. Gurtner, MD, FACS Stanford University School of Medicine, Palo Alto, CA, USA PURPOSE: It is well known that Wnt signaling plays a central role in various forms of fibrosis and has been implicated in pulmonary, renal, liver and skin fibrosis. Multiple studies have unraveled that activation of the canonical Wnt pathway stimulates fibroblast and myofibroblast activation and thus increases excessive collagen deposition resulting in fibrosis. Genetic and pharmacological blockage of different Wnt markers in experimental settings improves fibrotic disease models with direct translational implications for future therapies.
METHODS:
Capsular fibrosis was induced by inserting a silicone implant in a subcutaneous pocket in C57/ BL6 mice and in Wnt11-knockout mice. Hematoxylin and eosin staining (H&E) was done to qualitatively asses the morphology, including the density of the capsules. Cells from the murine capsules were isolated and characterized by fluorescence-activated cell scanning (FACS), single cell quantitative polymerase chain reaction (qPCR) and single cell RNA sequencing to determine the cells responsible for the fibrotic response. For imaging purposes SEM, TEM and 3D confocal imaging of the capsules were performed.
RESULTS: FACS analysis and immunohistochemistry stains revealed that collagen depositing macrophages are responsible for the development of capsular fibrosis. qPCR revealed that the majority of the myeloid cells in the fibrotic capsule expressed macrophage genes and were found to significantly increase Col1a1 as well as Wnt11. Therefore, we looked at an intervention to reduce these macrophages by using Wnt11-knockout mice and subsequent induction of fibrosis in these mice. Using transcriptional analysis we found distinct markers to differentiate three macrophage subgroups (Group 1= Cd36, Group 2= Cd209, Group 3= Ccr2). FACS revealed that Cd36 and Ccr2 were significantly reduced in the capsule of Wnt11-knockout mice compared to Bl6 mice. Furthermore, Wnt11-knockout mice displayed significantly thinner capsules with a lower cellularity and loosely arranged fibers compared to the capsule of Bl6-mice after 3 months, confirmed by H&E stains. Our findings suggest that these cell subgroups are essential to capsule development through pro-fibrotic activity.
CONCLUSION:
For the first time, we identify macrophage subgroups that are essential to capsule development through pro-fibrotic activity. Furthermore, we use a methodology to decrease capsular fibrosis in an animal model. These findings have promising therapeutic implications for the treatment of fibrosis around implants.
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